According to our findings and published data, oral semaglutide at a dose of 14 mg is significantly less effective for weight loss in individuals with obesity than tirzepatide (a dual GLP-1 and GIP agonist). Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.